Press Releases

Date Title and Summary Additional Formats
Toggle Summary Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Adult Partial Seizures
Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Adult Partial Seizures BRANFORD, Conn., May 4 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on novel drugs to treat serious neurological disorders, today announced that it is enrolling...
View HTML
Toggle Summary Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Infantile Spasms
Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Infantile Spasms BRANFORD, Conn., Feb. 28 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a specialty pharmaceutical company focused on novel drugs to treat serious neurological disorders, today announced the dosing of the first...
View HTML
Toggle Summary Marinus Pharmaceuticals Raises $29.4 Million in Series A Financing.
Marinus Pharmaceuticals Raises $29.4 Million in Series A Financing. BRANFORD, Conn., Oct. 25 /PRNewswire/ -- Marinus Pharmaceuticals, Inc., a new developer of drugs to treat serious central nervous system disorders, today announced the closing of a $29.4 million Series A financing round....
View HTML